Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials

Br J Dermatol. 2024 Jan 23;190(2):289-291. doi: 10.1093/bjd/ljad435.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Clinical Trial, Phase III

MeSH terms

  • Antibodies, Monoclonal
  • Dermatitis, Atopic*
  • Double-Blind Method
  • Humans
  • Pruritus
  • Severity of Illness Index
  • Sleep
  • Treatment Outcome

Substances

  • lebrikizumab
  • Antibodies, Monoclonal